PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday

  • Chardan Capital raised PDS Biotechnology Corporation PDSB price target from $15 to $16. . Chardan Capital analyst Geulah Livshits maintained the stock with a Buy rating. PDS Biotechnology shares rose 26.1% to close at $7.06 on Monday.
  • SVB Leerink boosted the price target on Lantheus Holdings, Inc. LNTH from $110 to $120. SVB Leerink analyst Roanna Ruiz maintained an Outperform rating on the stock. Lantheus Holdings shares rose 1.4% to close at $57.25 on Monday.
  • Oppenheimer cut Akoustis Technologies, Inc. AKTS price target from $8 to $7. Oppenheimer analyst Rick Schafer maintained an Outperform rating on the stock. Akoustis Technologies shares fell 2.2% to $3.49 in pre-market trading.
  • Barclays raised ImmunoGen, Inc. IMGN price target from $8 to $9. Barclays analyst Peter Lawson maintained an Overweight rating on the stock. ImmunoGen jumped 10.4% to $6.36 in pre-market trading.
  • Piper Sandler raised Shoals Technologies Group, Inc. SHLS price target from $28 to $30. Piper Sandler analyst Kashy Harrison maintained the stock with a Neutral. Shoals Technologies shares gained 17.3% to $26.36 in pre-market trading.
  • Chardan Capital reduced Better Therapeutics, Inc. BTTX price target from $17 to $14. Chardan Capital analyst Keay Nakae maintained a Buy rating on the stock. Better Therapeutics shares rose 1% to $1.50 in pre-market trading.

Check out this: HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: NewsPenny StocksPrice TargetSmall CapPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!